Small molecule · Inhibitor of sodium/hydrogen exchanger 3 (SLC9A3) · developed by Ardelyx
Tenapanor is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter on the apical surface of the small intestine and colon epithelium. By reducing sodium absorption and phosphate permeability through the paracellular pathway, it lowers intestinal phosphate uptake. It is studied in chronic kidney disease, constipation-predominant irritable bowel syndrome, and chronic idiopathic constipation.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 28, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05995899 | Phase 4 | IBS | Completed | ARDX |
| NCT07382167 | Phase 3 | Chronic Idiopathic Constipation (CIC) | Recruiting | ARDX |
| NCT05643534 | Phase 3 | Irritable Bowel Syndrome With Constipation (IBS-C) | Completed | ARDX |
| NCT01923428 | Phase 2/3 | Constipation Predominant Irritable Bowel Syndrome | Completed | ARDX |
| NCT01764854 | Phase 2 | End Stage Renal Disease | Completed | ARDX |
| NCT01340053 | Phase 2 | Constipation Predominant Irritable Bowel Syndrome | Completed | ARDX |
| NCT02226783 | Phase 1 | Healthy Volunteers Food Interaction Study | Completed | ARDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Idiopathic Constipation (CIC)Chronic Kidney Disease Stage 5Constipation Predominant Irritable Bowel SyndromeEnd Stage Renal DiseaseESRDHealthy Volunteers Food Interaction StudyIBSIBS - Irritable Bowel SyndromeIrritable Bowel Syndrome With Constipation (IBS-C)
Updated Oct 11, 2026. Something wrong or missing? Report it on the ARDX page.
See ARDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARDX catalysts and pipeline →